Regenxbio said Thursday that its Duchenne muscular dystrophy gene therapy met the bar in a pivotal study, and it’s aiming for FDA approval in 2027.
Regenxbio said Thursday that its Duchenne muscular dystrophy gene therapy met the bar in a pivotal study, and it’s aiming for FDA approval in 2027.
…
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission
With new data, Regenxbio to seek FDA approval of Duchenne gene therapy
BeOne wins FDA approval in lymphoma race
Biogen pushing tau drug forward despite Alzheimer’s study failure
Five years after disaster, a rare disease community gets new chance at treatment
NHS drugs go-ahead offers lifeline to children with rare muscle-wasting disease
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod
Drug meant to make gene therapy safer may also make it less effective
Biogen advances Alzheimer's drug to late-stage trial despite disappointing data
Capsida says it still doesn’t know what caused gene therapy death
